The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Psoriasis is considered to be a persistent skin disorder that is characterized mainly by skin irritation and scaly rashes where the skin cells multiply up to 10 times faster than normal. Psoriasis majorly affects the knees, elbows, and scalp. The major objective of the therapy for this disease is to stop the skin cells from growing so quickly. The therapeutic approach for psoriasis depends upon the severity and amount of skin affected by the same.
The global Psoriasis Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Psoriasis Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Psoriasis Therapeutics.
Report Scope
The Psoriasis Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Psoriasis Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Psoriasis Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company (Partial List):
- Astellas Pharma Inc.
- AstraZeneca plc
- Boehringer Ingelheim GmbH
- F. Hofffmann-La Roche
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Valeant Pharmaceuticals International, Inc.
- Biocon Limited
- Eli Lilly and Company
- G & W Laboratories Inc.
Segment by Type
- TNF Inhibitors
- PDE4 Inhibitors
- Interleukin Blockers
- Others
Segment by Application
- Oral
- Parenteral
- Topical
By Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina)
- Middle East & Africa (Turkey, Saudi Arabia, UAE)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Psoriasis Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Psoriasis Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 TNF Inhibitors
1.2.3 PDE4 Inhibitors
1.2.4 Interleukin Blockers
1.2.5 Others
1.3 Market by Application
1.3.1 Global Psoriasis Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oral
1.3.3 Parenteral
1.3.4 Topical
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Psoriasis Therapeutics Market Perspective (2019-2030)
2.2 Psoriasis Therapeutics Growth Trends by Region
2.2.1 Global Psoriasis Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Psoriasis Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Psoriasis Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Psoriasis Therapeutics Market Dynamics
2.3.1 Psoriasis Therapeutics Industry Trends
2.3.2 Psoriasis Therapeutics Market Drivers
2.3.3 Psoriasis Therapeutics Market Challenges
2.3.4 Psoriasis Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Psoriasis Therapeutics Players by Revenue
3.1.1 Global Top Psoriasis Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Psoriasis Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Psoriasis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Psoriasis Therapeutics Revenue
3.4 Global Psoriasis Therapeutics Market Concentration Ratio
3.4.1 Global Psoriasis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Psoriasis Therapeutics Revenue in 2023
3.5 Psoriasis Therapeutics Key Players Head office and Area Served
3.6 Key Players Psoriasis Therapeutics Product Solution and Service
3.7 Date of Enter into Psoriasis Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Psoriasis Therapeutics Breakdown Data by Type
4.1 Global Psoriasis Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Psoriasis Therapeutics Forecasted Market Size by Type (2025-2030)
5 Psoriasis Therapeutics Breakdown Data by Application
5.1 Global Psoriasis Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Psoriasis Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Psoriasis Therapeutics Market Size (2019-2030)
6.2 North America Psoriasis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Psoriasis Therapeutics Market Size by Country (2019-2024)
6.4 North America Psoriasis Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Psoriasis Therapeutics Market Size (2019-2030)
7.2 Europe Psoriasis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Psoriasis Therapeutics Market Size by Country (2019-2024)
7.4 Europe Psoriasis Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Psoriasis Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Psoriasis Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Psoriasis Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Psoriasis Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Psoriasis Therapeutics Market Size (2019-2030)
9.2 Latin America Psoriasis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Psoriasis Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Psoriasis Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Psoriasis Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Psoriasis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Psoriasis Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Psoriasis Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Astellas Pharma Inc.
11.1.1 Astellas Pharma Inc. Company Detail
11.1.2 Astellas Pharma Inc. Business Overview
11.1.3 Astellas Pharma Inc. Psoriasis Therapeutics Introduction
11.1.4 Astellas Pharma Inc. Revenue in Psoriasis Therapeutics Business (2019-2024)
11.1.5 Astellas Pharma Inc. Recent Development
11.2 AstraZeneca plc
11.2.1 AstraZeneca plc Company Detail
11.2.2 AstraZeneca plc Business Overview
11.2.3 AstraZeneca plc Psoriasis Therapeutics Introduction
11.2.4 AstraZeneca plc Revenue in Psoriasis Therapeutics Business (2019-2024)
11.2.5 AstraZeneca plc Recent Development
11.3 Boehringer Ingelheim GmbH
11.3.1 Boehringer Ingelheim GmbH Company Detail
11.3.2 Boehringer Ingelheim GmbH Business Overview
11.3.3 Boehringer Ingelheim GmbH Psoriasis Therapeutics Introduction
11.3.4 Boehringer Ingelheim GmbH Revenue in Psoriasis Therapeutics Business (2019-2024)
11.3.5 Boehringer Ingelheim GmbH Recent Development
11.4 F. Hofffmann-La Roche
11.4.1 F. Hofffmann-La Roche Company Detail
11.4.2 F. Hofffmann-La Roche Business Overview
11.4.3 F. Hofffmann-La Roche Psoriasis Therapeutics Introduction
11.4.4 F. Hofffmann-La Roche Revenue in Psoriasis Therapeutics Business (2019-2024)
11.4.5 F. Hofffmann-La Roche Recent Development
11.5 GlaxoSmithKline plc
11.5.1 GlaxoSmithKline plc Company Detail
11.5.2 GlaxoSmithKline plc Business Overview
11.5.3 GlaxoSmithKline plc Psoriasis Therapeutics Introduction
11.5.4 GlaxoSmithKline plc Revenue in Psoriasis Therapeutics Business (2019-2024)
11.5.5 GlaxoSmithKline plc Recent Development
11.6 Merck & Co., Inc.
11.6.1 Merck & Co., Inc. Company Detail
11.6.2 Merck & Co., Inc. Business Overview
11.6.3 Merck & Co., Inc. Psoriasis Therapeutics Introduction
11.6.4 Merck & Co., Inc. Revenue in Psoriasis Therapeutics Business (2019-2024)
11.6.5 Merck & Co., Inc. Recent Development
11.7 Valeant Pharmaceuticals International, Inc.
11.7.1 Valeant Pharmaceuticals International, Inc. Company Detail
11.7.2 Valeant Pharmaceuticals International, Inc. Business Overview
11.7.3 Valeant Pharmaceuticals International, Inc. Psoriasis Therapeutics Introduction
11.7.4 Valeant Pharmaceuticals International, Inc. Revenue in Psoriasis Therapeutics Business (2019-2024)
11.7.5 Valeant Pharmaceuticals International, Inc. Recent Development
11.8 Biocon Limited
11.8.1 Biocon Limited Company Detail
11.8.2 Biocon Limited Business Overview
11.8.3 Biocon Limited Psoriasis Therapeutics Introduction
11.8.4 Biocon Limited Revenue in Psoriasis Therapeutics Business (2019-2024)
11.8.5 Biocon Limited Recent Development
11.9 Eli Lilly and Company
11.9.1 Eli Lilly and Company Company Detail
11.9.2 Eli Lilly and Company Business Overview
11.9.3 Eli Lilly and Company Psoriasis Therapeutics Introduction
11.9.4 Eli Lilly and Company Revenue in Psoriasis Therapeutics Business (2019-2024)
11.9.5 Eli Lilly and Company Recent Development
11.10 G & W Laboratories Inc.
11.10.1 G & W Laboratories Inc. Company Detail
11.10.2 G & W Laboratories Inc. Business Overview
11.10.3 G & W Laboratories Inc. Psoriasis Therapeutics Introduction
11.10.4 G & W Laboratories Inc. Revenue in Psoriasis Therapeutics Business (2019-2024)
11.10.5 G & W Laboratories Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
